** PrEP in the Balance: Hopes and fears in 2025
------------------------------------------------------------
March 27, 2025

Dear Advocate,

A new AVAC blog, PrEP in the Balance: Hopes and Fears in 2025, outlines the promise of next-generation HIV prevention, the challenges posed by the new US administration, and shares new resources to secure a future for PrEP research, development, and access.

"The global health community ended 2024 with a historic opportunity in sight. With key lessons in hand from the rollout of oral PrEP, ([link removed]) it is possible to get rollout right in 2025 with next generation long-acting PrEP and put the world on track to end the AIDS epidemic by 2030... But as the new US administration took control of the government at the end of January and decimated every aspect of foreign aid and global health, the impacts could set back the HIV response by decades, allowing the epidemic to resurge.”
— AVAC's Jeanne Baron and Catherine Verde Hashim

This piece covers the impact of the foreign assistance freeze on PrEP, risks from the failure to reauthorize PEPFAR, critical lessons from the rollout of oral PrEP, and new data on long-acting injectables. Read on for these resources.

Read the blog: [link removed]


** PrEP Resources and Insights
------------------------------------------------------------
* Impact of the Stop-Work Order on PrEP: ([link removed]) The PEPFAR stop-work orders on HIV prevention outcomes is expected to be severe. This webpage ([link removed]) shares the effect of these orders, including widespread disruptions across the HIV prevention field—including halted PrEP services, stalled product introductions (with PEPFAR’s CAB rollout paused), terminated research studies, and significant reductions in healthcare workforce.

* Join AVAC and GBGMC on Thursday, 3 April for the next “Fight For Our Lives” Emergency Townhall ([link removed]) to learn more about how the recent freeze on US government foreign assistance has impacted the availability of PrEP ([link removed]) , including the rollout of injectable cabotegravir for PrEP, and what this means for key populations and LGBTQ+ communities.

* AVAC’s PrEPWatch shares a comprehensive update on PrEP, coming out of CROI 2025 ([link removed]). "These advances in the field make clear how much is at stake. Innovation in long-acting PrEP and new evidence to support on-demand PrEP among women could transform global health, if the field can unite behind the evidence and refuse to be defeated.”

* The Spotlight South Africa article, A jab that could protect against HIV for a year at a time ([link removed]) is a comprehensive overview of new long-acting prevention and treatment research presented at CROI.

* Rollout of LEN for PrEP: Bhekisisa reports ([link removed]) that the Global Fund plans to roll out a twice-yearly anti-HIV jab, with or without PEPFAR support. For more info on LEN go to AVAC’s dedicated page on lenacapavir ([link removed]) to find reports on delivery ([link removed]) and clinical trials testing ([link removed]).

The promise of HIV prevention is just as real as it was before the new administration took office. Only now, we must find a new path. To stay on track will require trust, innovation, commitment and investment.

Best,
AVAC

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe

Contact Us T: +1 212 796 6423
E: ** [email protected]
W: ** www.avac.org
** www.twitter.com/hivpxresearch
** www.facebook.com/hivpxresearch
** www.youtube.com/hivpxresearch
==============================================

Unsubscribe [email protected] from this list:
[link removed]